30秒注册登陆，可查看更多信息，结交更多好友，享用更多功能，轻松玩转论坛，白白手拉手欢迎您的加入！
您需要 登录 才可以下载或查看，没有账号？注册新成员
x
白白是个顽疾，我知道大家特别期待JAK，希望这剂神药可以治愈白白，我也非常好奇它究竟有多神奇。 千等万等终于上市了，相信有些有渠道的朋友会去找美国代购买JAK。这几天我也一直关注与JAK相关的报道，翻墙搜了个遍，通过外网的一些信息，了解到这个药有一定的副作用，且药品本身有FDA副作用的装箱警告。 毕竟是新药，相关帖子不多，尤其在国内，在没有医生的指点下，怕有些白白朋友盲目试药，所以先总结了这篇关于副作用的帖子。我平时会写一些与白白相关的帖子，习惯在知乎跟大家分享。这两天看到这个药的副作用，且国内没有相关JAK副作用的帖子，害怕大家急于赶快试药，为了同胞们的健康，为了让更多的同胞看到，想跟大家提个醒，所以我在咱们手拉手上注册了这个账号，将我这两天写的这两篇帖子发表过来。
所有信息都是我从外网看的，这些文章的出处都是官方或者知名医疗网站，但我不保证信息的正确性，包括我的翻译，信息出处链接我有保留，如果有人感兴趣可以给我留。 治疗白白，记得一定要三甲，一定要听从医嘱。
------------------------------------------------
近几年一直炒得很火的所谓的白癜风“神药“，（也就是我们常说的JAK）incyte corp.的鲁索利替尼(Ruxolitinib)在2021年的9月21日，FDA已经批准上市，这也成为了美国批准的第一种，也是唯一一种局部JAK抑制剂，上市的同时，大量相关的细节也都一起披露了，我这两天翻墙将JAK的相关报道全看了一遍，总结了一些我感觉还算比较干货的内容，接下来几天我会整理总结，与大家分享。
（随着时间发展，我相信对JAK的相关报道会有更多，关注植泰肤色纹色遮盖，我会继续为大家分享JAK相关干货，以及其他白癜风相关治疗信息。）
我这篇帖子更多的是想强调这款“神剂”的副作用。 因为Incyte在特应性皮炎（AD）中获得FDA批准使用鲁索利替尼ruxolitinib乳膏，附有与类别相关的装箱警告。
其次我想说明一点，通过目前所披露的信息，鲁索利替尼（Jak）确实可以显著减轻特应性皮炎引起的皮肤炎症和瘙痒，且针对目前所披露的测试情况来看这款JAK乳膏对白癜风也是有一定治疗效果，但是目前此药剂还是只针对于皮炎对应药来推广的，目前并没有在官方说明书中提到白癜风。
白癜风作为这个药的对应症状之一还在进一步测试中，还没问完全做出一个肯定的结论。在目前所披露的资料中表明，针对白癜风的临床测试，目前还在处在三期测试中，大概在年底的时候针对白癜风的论证实验会结束，届时有可能会将白癜风加入他们的说明书。
以下是券商针对INCYTE公司新上市的鲁索利替尼(Ruxolitinib)/JAK，做出的调研报告：
原文出在雅虎金融板块。无关紧要部分我做了删减。我将原文及对应的翻译一起发上来。
提醒一下着急试用此药的白白朋友们，jak有一定的副作用，一定要谨慎，一定要定从医嘱！！！
题目：Incyte Announces U.S. FDA Approval of Opzelura (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD) 题目：INcyte公司宣布美国食品及药物管理局批准使用JAK抑制剂Opzelura(Ruxolitinib)乳膏治疗特应性皮炎(AD)
Opzelura is the first and only topical Janus kinase (JAK) inhibitor approved in the United States - Opzelura是美国批准的第一种也是唯一一种局部的Janus激酶(JAK)抑制剂。
In Phase 3 studies, Opzelura significantly reduced the skin inflammation and itch associated with AD - 在第三阶段的研究中，Opzelura显着地减少了与AD相关的皮肤炎症和瘙痒。
WILMINGTON, Del., September 21, 2021--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura (ruxolitinib) cream for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Opzelura is the first and only topical formulation of a JAK inhibitor approved in the United States. Research shows dysregulation of the JAK-STAT pathway contributes to key features of AD such as itch, inflammation and skin barrier dysfunction. 特拉华州威尔明顿，2021年9月21日--(商业导线美国食品和药物管理局(食品和药物管理局)今天宣布，美国食品和药物管理局(Fda)已批准Opzelura(Ruxolitinib)乳膏用于治疗12岁或12岁以上的，非免疫障碍患者的轻度至中度特应性皮炎(AD) 短期和非持续性慢性治疗。Opzelura是第一种，也是唯一一种在美国获得批准的JAK抑制剂的局部配方。研究表明JAK-STAT通路的失调导致了AD（特应性皮炎）他的主要特征有：如瘙痒、炎症和皮肤屏障功能障碍。
"Atopic dermatitis is a chronic immune-mediated disease that can be challenging to manage. Many patients do not respond well to existing treatments and have uncontrolled disease," said Jonathan Silverberg, M.D., Ph.D., M.P.H., Associate Professor of Dermatology and Director of Clinical Research and Contact Dermatitis at The George Washington University School of Medicine and Health Sciences. "As a clinician, I am excited to have a non-steroidal topical cream like Opzelura." 乔治华盛顿大学医学与健康科学学院皮肤科副教授、临床研究与接触性皮炎主任乔纳森·西尔弗伯格(Jonathan Silverberg)说：“特应性皮炎是一种慢性免疫介导的疾病，很难管理。许多患者对现有的治疗方法反应不佳，而且有不受控制的疾病。”医学博士乔纳森·西尔弗伯格(Jonathan Silverberg)是皮肤科副教授兼临床研究与接触性皮炎主任。“作为一名临床医生，我很高兴有一种像Opzelura这样的非类固醇外用霜。”
"The approval of Opzelura is an important advancement in the treatment of AD, and we are pleased to offer a novel topical treatment option that targets a pathway believed to be a source of inflammation," said Hervé Hoppenot, Chief Executive Officer, Incyte. "At Incyte, we are committed to transforming the treatment of immune-mediated dermatologic conditions like AD. We look forward to bringing Opzelura to the patient community and also continuing to explore its potential in other challenging skin diseases." “Opzelura的批准是治疗AD的一项重要进展，我们很高兴提供一种新的局部治疗方案，其目标是一种被认为是炎症来源的途径，”INCYTE公司首席执行官Hervé Hoppenot说。我们致力于改变对免疫介导的皮肤病(如AD)的治疗。我们期待着将Opzelura带给患者社区，并继续探索其在其他具有挑战性的皮肤病中的潜力。“
The FDA approval was based on data from the TRuE-AD (Topical Ruxolitinib Evaluation in Atopic Dermatitis) clinical trial program, consisting of two randomized, double-blind, vehicle-controlled Phase 3 studies (TRuE-AD1 and TRuE-AD 2) evaluating the safety and efficacy of Opzelura in more than 1,200 adolescents and adults with mild to moderate AD. Results from the studies showed patients experienced significantly clearer skin and itch reduction when treated with Opzelura cream 1.5% twice daily (BID), compared to vehicle (non-medicated cream): FDA的批准是基于TRuE-AD(特发性皮炎评估)临床试验项目的数据，包括两个随机、双盲、车辆控制的第三阶段研究(TRuE-ad1和TRuE-AD-2)，评估Opzelura对1,200多名青少年和轻度至中度AD患者的安全性和有效性。研究结果显示，与车辆(非药物霜)相比，使用Opzelura乳膏(每日两次)1.5%时，患者的皮肤和瘙痒明显减轻：
·Significantly more patients treated with Opzelura achieved Investigator’s Global Assessment (IGA) Treatment Success (IGA-TS, primary endpoint) at Week 8 (defined as an IGA score of 0 [clear] or 1 [almost clear] with at least a 2-point improvement from baseline): 53.8% in TRuE-AD1 and 51.3% in TRuE-AD2, compared to vehicle (15.1% in TRuE-AD1, 7.6% in TRuE-AD2; P<0.0001). 值得注意的是，接受Opzelura治疗的患者在第8周取得了调查员的全球评估(IGA-TS，主要终点)的成功(定义为IGA评分为0[清楚]或1[几乎清楚]，至少比基线提高了2分)：53.8%在TRuE-AD1和51.3%在TRuE-AD2，而车辆(15.1%的TRuE-AD1，7.6%的TRuE-AD2；P<0.0001)。 · Significantly more patients treated with Opzelura experienced a clinically meaningful reduction in itch from baseline at Week 8, as measured by a ≥4-point reduction in the itch Numerical Rating Scale (itch NRS4): 52.2% in TRuE-AD1 and 50.7% in TRuE-AD2, compared to vehicle (15.4% in TRuE-AD1, 16.3% in TRuE-AD2; P<0.0001), among patients with an NRS score of at least 4 at baseline. 更多接受Opzelura治疗的患者在第8周经历了临床上有意义的瘙痒减少，如瘙痒数值评分量表(瘙痒NRS 4)中的≥4分降低：植在泰True-ad1和肤True-AD2色中纹分色别为52.2%和50.7%，而在基线NRS评分至少为4分的患者中，前者为15.4%，16.3%为真AD2；P<0.0001。
In clinical trials, the most common (≥1%) treatment-emergent adverse reactions in patients treated with Opzelura were nasopharyngitis, diarrhea, bronchitis, ear infection, eosinophil count increased, urticaria, folliculitis, tonsillitis and rhinorrhea2. See Important Safety Information below, including Boxed Warnings for serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis, seen with JAK inhibitors for inflammatory conditions. 在临床试验中，最常见的(≥1%)治疗副反应是鼻咽炎、腹泻、支气管炎、耳部感染、嗜酸性粒细胞计数增加、荨麻疹、毛囊炎、扁桃体炎和鼻漏。 请参阅下面的重要安全信息，包括严重感染、死亡率、恶性肿瘤、主要不良心血管事件和血栓形成的装箱警告，与JAK抑制剂一起用于治疗炎症情况。
"It can be hard for people to fully appreciate how difficult AD can be and the tremendous impact it has on patients," said Julie Block, President & CEO, National Eczema Association. "The chronic itch is difficult to cope with and related sleep issues can be exhausting. Many patients and their dermatologists are looking for additional optios to meet current unmet needs in the management of AD. The approval of Opzelura is exciting news, and we welcome a new treatment option for our community." 美国国家湿疹协会总裁兼首席执行官朱莉·布洛克(Julie Block)说：“植人泰们很难分认识到AD有多困难，以及它对患者的巨大影响。”“慢性瘙痒很难解决，相关纹的色睡眠问题可能令人精疲力竭。许多患者及其皮肤科医生正在寻找更多的遮盖选择，以满足目前在治疗AD方面未得到满足的需求。Opzelura的批准是令人兴奋的消息，我们欢迎我们的社区采取新的治疗方案。”
AD is a chronic skin disease affecting more than 21 million people aged 12 years and older in the U.S. and is characterized by inflammation and itch3. Signs and symptoms include irritated and itchy skin that can cause red lesions that may ooze and crust. People with AD are also more susceptible to bacterial, viral and fungal infections4. 在美国，AD是一种慢性皮肤病，影响超过2100万12岁及以上的人，其特点是发炎和瘙痒。体征和症状包括刺激性和瘙痒的皮肤，可能导致红色的损害，可能渗出和外壳。患有AD的人也更容易受到细菌、病毒和真菌感染。
About TRuE-AD / 关于TRuE-AD The TRuE-AD clinical trial program evaluating the safety and efficacy of ruxolitinib cream compared to vehicle (non-medicated cream) in patients with atopic dermatitis (AD) consists of two randomized, double-blind, vehicle-controlled Phase 3 studies: TRuE-AD1 (NCT03745638) and TRuE-AD2 (NCT03745651). Both studies enrolled more than 600 patients (age ≥12 years) who had been previously diagnosed with AD for at least two years and who were candidates for topical therapy. Key findings from the TRuE-AD1 and TRuE-AD2 studies were presented at the European Academy of Dermatology and Venereology (EADV) Congress, Revolutionizing Atopic Dermatitis Virtual Symposium and previously announced by Incyte. 真正的AD临床试验计划评估鲁司利替尼乳膏与车辆(非药物乳膏)治疗特应性皮炎(AD)的安全性和有效性，包括两项随机、双盲、车辆控制的第三阶段研究：TRuE-AD1(NCT 03745638)和TRuE-AD2(NCT 03745651)。这两项研究都吸收了600多名患者(年龄为≥12岁)，他们此前被诊断患有AD至少两年，他们都是外用治疗的候选对象。 来自TRuE-AD1和TRuE-AD2的主要研究结果被提交给了植泰肤色遮盖与性病学会(EADV)大会, 革命性的特发性皮炎虚拟研讨会之前被英特所宣布。
About Opzelura (ruxolitinib) Cream / 关于Opzelura (鲁克索利替尼)乳膏 Opzelura, a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is the first and only topical JAK inhibitor approved for use in the United States for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Use of Opzelura in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants, such as azathioprine or cyclosporine, is not recommended. Opzelura是因细胞选择性JAK 1/JAK 2抑制剂Ruxolitinib的一种新型乳膏配方，是第一种也是唯一一种在美国被批准使用的局部JAK抑制剂，用于非免疫功能低下的12岁及12岁以上患者的局部短期和非持续的慢性特应性皮炎(AD)的局部处方药治疗，或者当这些治疗不可取时。不建议使用Opzelura与治疗性生物制剂、其他JAK抑制剂或强效免疫抑制剂(如硫唑嘌呤或环孢素)联合使用
Additionally, ruxolitinib cream is in Phase 3 development for the treatment of adolescents and adults with vitiligo in the TRuE-V clinical program. Results from this Phase 3 program were recently announced. 此外，Ruxolitinib乳膏在第三阶段开发，用于治疗青少年和成人白癜风的TRuE-V临床计划。这个第三阶段的结果会最近宣布.
Incyte has worldwide rights for the development and commercialization of ruxolitinib cream, marketed in the United States as Opzelura. Opzelura is a trademark of Incyte. 英特公司在世界范围内拥有开发和商品化鲁索利替尼乳膏的权利，在美国市场上被称为Opzelura。Opzelura是英特的商标。
划重点了： IMPORTANT SAFETY INFORMATION / 重要安全信息 OPZELURA cream is for use on the skin only. Do not use OPZELURA cream in your eyes, mouth or vagina. OPZELURA乳膏只用于皮肤。不要在眼睛、口腔或阴道里使用OPZELURA乳膏。 OPZELURA may cause serious side effects, including: OPZELURA可能造成严重的副作用，包括： Serious Infections: OPZELURA cream contains ruxolitinib. Ruxolitinib belongs to a class of medicines called Janus kinase (JAK) inhibitors. JAK inhibitors are medicines that affect your immune system. JAK inhibitors can lower the ability of your immune system to fight infections. Some people have had serious infections while taking JAK inhibitors by mouth, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized or died from these infections. Some people have had serious infections of their lungs while taking OPZELURA. Your healthcare provider should watch you closely for signs and symptoms of TB during treatment with OPZELURA. 严重感染：OPZELURA乳膏含有鲁克索利替尼。Ruxolitinib属于一种叫做JAK抑制剂的药物。Jak抑制剂是影响免疫系统的药物。Jak抑制剂可以降低免疫系统抵抗感染的能力。一些人在口服JAK抑制剂时感染严重，包括肺结核(TB)，以及由细菌、真菌或可在全身传播的病毒引起的感染。一些人已经住院或死于这些感染。有些人在服用OPZELURA时肺部感染严重。在使用OPZELURA治疗期间，您的医疗保健提供者应该密切监视您是否有结核病的迹象和症状。 OPZELURA should not be used in people with an active, serious infection, including localized infections. You should not start using OPZELURA if you have any kind of infection unless your healthcare provider tells you it is okay. You may be at a higher risk of developing shingles (herpes zoster) while using OPZELURA. OPZELURA不应用于有活动性、严重感染的人，包括局部感染。你不应该开始使用OPZELURA，如果你有任何类型的感染，除非你的医疗保健提供者告诉你，这是可以的。使用OPZELURA时，您可能会有更高的风险发展带状疱疹(带状疱疹)。 Incrased risk of death from all causes, including sudden cardiac death, has happened in people taking JAK inhibitors by mouth. 口服JAK抑制剂的人因各种原因死亡的风险增加，包括心脏猝死。 Cancer and immune system problems: OPZELURA may increase your risk of certain cancers by changing the way your immune system works. Some people have had lymphoma and other cancers while taking JAK inhibitors by mouth, especially if they are a current or past smoker. Some people have had skin cancers while taking OPZELURA. Your healthcare provider will regularly check your skin during your treatment with OPZELURA. 癌症和免疫系统问题：OPZELURA可以植通过改变免疫系统的工作方式来增加你患某些癌症的风险。一些人在口服JAK抑制剂时患有淋巴瘤和其他癌症，尤其是当他们是现在或过去的吸烟者时。有些人在服用OPZELURA时患皮肤癌。在泰使用OPZELURA治疗期间，您的医疗保健提供者将定期检查您的皮肤。 There is an increased risk of major cardiovascular events such as heart attack, stroke or cardiac death in people with cardiovascular risk factors and who are current or past smokers while using JAK inhibitors to treat inflammatory conditions. 在使用JAK抑制剂治疗炎性疾病时，患有心血管危险因素的人以及目前或过去吸烟的人发生重大心血管事件(如心脏病发作、中风或心源性死亡)的风险增加。 Blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) can happen in some people taking OPZELURA. This may be life-threatening. 血块：在一些服用OPZELURA的人中，腿部静脉血栓(深静脉血栓，DVT)或肺部血栓(肺栓塞，PE)可能会发生血块。这可能会危及生命。 Low blood cell counts: OPZELURA may cause low platelet counts (thrombocytopenia), low red blood cell counts (anemia), and low white blood cell counts (neutropenia). If needed, your healthcare provider will do a blood test to check your blood cell counts during your treatment with OPZELURA and may stop your treatment if signs or symptoms of low blood cell counts happen. 低血细胞计数：OPZELURA可引起血小板减少(血小板减少)、红细胞计数(贫血)和白细胞计数(中性粒细胞减少)。如果需要的话，你的医疗保健提供者将在你使用OPZELURA治疗期间做一次血液测试来检查你的血细胞计数，如果出现低血细胞计数的迹象或症状，可能会停止你的治疗。 Cholesterol increases: Cholesterol increase has happened in people when ruxolitinib is taken by mouth. Tell your healthcare provider if you have high cholesterol or tiglycerides. 胆固醇增加：当口服鲁克索利替尼时，胆固醇的增加发生在人们身上。告诉你的医疗保健提供者，如果你有高胆固醇或甘油三酯。 Before starting OPZELURA, tell your healthcare provider if you: 在启动OPZELURA之前，请告诉您的医疗服务提供商: ·have an infection, are being treated for one, or have an infection that keeps coming back 感染，正在接受治疗，或者感染不断复发。 ·have diabetes, chronic lung disease, HIV, or a weak immune system 患有糖尿病、慢性肺病、艾滋病或免疫系统薄弱。 ·have TB or have been in close contact with someone with TB 曾否结核病或曾与结核病患者有密切接触 ·have had shingles (herpes zoster) or hepatitis B or C 曾有带状疱疹或乙型肝炎或丙型肝炎 ·live, have lived in, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance for getting certain kinds of fungal infections. These infections may happen or become more severe if you use OPZELURA. Ask your healthcare provider if you do not know if you have lived in an area where these infections are common. ·在美国的某些地区(如俄亥俄、密西西比河流域和西南部)，有更多的机会受到某些种类的真菌感染。如果使用OPZELURA，这些感染可能会发生或变得更加严重。问问你的医疗保健提供者，如果你不知道你是否生活在一个地区，这些感染是常见的。 · ·think you have an infection or have symptoms of an infection such as: 认为你感染或有感染的症状，如： ·have ever had any type of cancer, or are a current or past smoker. 曾经有过任何类型的癌症，或者是现在或过去的吸烟者。 · ·have had blood clots in the veins of your legs or lungs in the past. 过去你的腿部或肺部的静脉里有血块。 · ·have high cholesterol or triglycerides 高胆固醇或高甘油三酯 ·have or have had low white or red blood cell counts ·有或曾经有过较低的白细胞或红细胞计数。 · ·are pregnant or plan to become pregnant. It is not known if OPZELURA will harm your unborn baby. There is a pregnancy exposure registry for individuals who use OPZELURA during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. If you become exposed to OPZELURA during pregnancy, you and your healthcare provider should report exposure to Incyte Corporation 怀孕或计划怀孕。目前还不清楚OPZELURA是否会伤害你未出生的婴儿。在怀孕期间使用OPZELURA的个人有怀孕暴露登记。本注册表的目的是收集有关您和您的婴儿健康的信息。如果你在怀孕期间暴露于OPZELURA，你和你的医疗保健提供者应该报告给Incyte公司。
·are breastfeeding or plan to breastfeed. It is not known if OPZELURA passes into your breast milk. Do not breastfeed during treatment with OPZELURA and for about 4 weeks after the last dose. 母乳喂养或计划母乳喂养。还不知道OPZELURA是否会进入您的母乳。在OPZELURA治疗期间和最后一次剂量后4周内不要母乳喂养。
·After starting OPZELURA: / 开始使用OPZELURA后： ·Call your healthcare provider right away if you have any symptoms of an infection. OPZELURA can make you more likely to get infections or make worse any infections that you have. 如果您有任何感染症状，请立即打电话给您的医疗服务提供商。OPZELURA可以使你更有可能感染或使任何你的感染更糟。
·Get emergency help right away if you have any symptoms of a heart attack or stroke while using OPZELURA, including: 如果您在使用OPZELURA时有心脏病发作或中风的任何症状，请立即寻求紧急帮助，包括：
·discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back 胸部中心的不适持续了几分钟，或者消失了，然后又回来了。
·severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw 严重的胸闷、疼痛、压力或胸部、喉咙、颈部或下巴的沉重
pain or discomfort in your arms, back, neck, jaw, or stomach 手臂、背部、颈部、下巴或胃部疼痛或不适
·shortness of breath with or without chest discomfort 气短伴或无胸部不适 ·breaking out in a cold sweat 冒出冷汗 ·nausea or vomiting 恶心或呕吐 ·feeling lightheaded 感觉头昏眼花 ·weakness in one part or on one side of your body 身体的一个部位或一侧的弱点 ·slurred speech 含糊不清的言语
·Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with OPZELURA, including: swelling, pain or tenderness in one or both legs, sudden, unexplained chest or upper back pain, or shortness of breath or difficulty breathing. 如果你在接受OPZELURA治疗时有任何血块的迹象和症状，包括：一条或两条腿的肿胀、疼痛或压痛、突然的、不明原因的胸痛或上腰痛、呼吸短促或呼吸困难，请立即告知你的医疗保健提供者。
·Tell your healthcare provider right away if you develop or have worsening of any symptoms of low blood cell counts, such as: unusual bleeding, bruising, tiredness, shortness of breath or fever. 告诉你的医疗保健提供者，如果你出现或有恶化的任何症状的低血细胞计数，如：异常出血，瘀伤，疲劳，呼吸急促或发烧。 Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vi**ins, and herbal supplements. ·告诉你的医护人员你服用的所有药物，包括处方和非处方药、维生素和草药补充剂。 The most common side effects of OPZELURA include: pain or swelling in your nose or throat (nasopharyngitis), diarrhea, bronchitis, ear infection, increase in a type of white blood cell counts (eosinophil), hives, inflamed hair pores (folliculitis), swelling of the tonsils (tonsilitis), and runny nose (rhinorrhea). OPZELURA最常见的副作用包括：鼻或咽喉疼痛或肿胀(鼻咽炎)、腹泻、支气管炎、耳部感染、白细胞计数增加(嗜酸细胞)、蜂窝、发炎毛孔(毛囊炎)、扁桃体肿胀(扁桃体炎)和流鼻涕(鼻漏)。 These are not all of the possible side effects of OPZELURA. Call your doctor for medical advice about side effects. 这些并不是OPZELURA可能产生的所有副作用。打电话给你的医生，寻求关于副作用的医学建议。
About Incyte Dermatology / 关于细胞皮肤病学 Incyte’s science-first approach and expertise in immunology has formed the foundation of the company. In Dermatology, the Company’s research and development efforts are focused on leveraging our knowledge of the JAK-STAT pathway to identify and develop topical and oral therapies with the potential to modulate immune pathways driving uncontrolled inflammation and help restore normal immune function. 英赛尔的科学第一的方法和专业的免疫学已经形成了公司的基础。在皮肤病学方面，该公司的研究和开发工作集中在利用我们对JAK-STAT通路的了解，以确定和开发局部和口服疗法，从而有可能调节免疫途径，驱动不受控制的炎症，并帮助恢复正常的免疫功能。
Currently, Incyte is exploring the potential of JAK inhibition for a number of immune-mediated dermatologic conditions with a high unmet medical need, including vitiligo and hidradenitis suppurativa. 目前，INCyte正在探索JAK抑制许多免疫介导的皮肤病的潜力，包括白癜风和化脓性汗炎。
About Incyte / 关于INCYTE Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. 英特公司是一家总部位于特拉华州威尔明顿的全球性生物制药公司，致力于通过发现、开发和商业化专利疗法，为严重的未满足的医疗需求寻找解决方案。 Forward-Looking Statements / 前瞻性陈述 Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding whether or when Opzelura might provide a successful treatment option for patients with atopic dermatitis, the Company’s ongoing clinical development program for ruxolitinib cream and its dermatology program generally, contain predictions, estimates, and other forward-looking statements. 除本新闻稿所列的历史信息外，本新闻稿中所列的事项，包括关于Opzelura是否或何时可为特应性皮炎患者提供成功治疗方案的声明、该公司正在进行的鲁克索利替尼霜临床开发方案及其皮肤科项目，包括预测、估计和其他前瞻性陈述。
再一次强调，鉴于JAK的副作用比较多，请想试用JAK的白白朋友们，一定要定从医嘱！！
| 
发表于 2021-9-23 22:26:58
楼主